A clinical trial to assess the effect of CBD on seizure frequency in dogs with idiopathic epilepsy
A randomized blinded controlled clinical trial study conducted in Colorado State University assessed the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy.
Dogs were randomly assigned to two groups: CBD group or placebo (14) group. The CBD group received orally CBD-infused oil (2.5 mg/kg twice daily) for 12 weeks in addition to existing antiepileptic treatments, and the placebo group received non-infused oil under the same conditions.
Clinically, CBD oil treatment had a significant reduction in seizure frequency of 33% compared with the placebo group. However, the proportion of dogs considered as responders to treatment (≥ 50% decrease in seizure activity) was similar between the groups. Plasma CBD concentrations were correlated with reduction in seizure frequency (r = -0.68). Dogs in the CBD group had a significant increase in serum alkaline phosphatase activity as was found in previous studies in dogs with osteoarthritis (OA). No side effects were reported by owners,
Although a significant reduction in seizure frequency was achieved for dogs, additional research is warranted to determine the proper dosage of CBD that would be effective in reducing seizure activity by ≥ 50%.
McGrath, Stephanie, et al. “Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.” Journal of the American Veterinary Medical Association 254.11 (2019): 1301-1308.